517 related articles for article (PubMed ID: 23566383)
41. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
Gardyszewska A; Czajkowski K
Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
[TBL] [Abstract][Full Text] [Related]
42. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
Wildemeersch D; Goldstuck ND; Jackers G
Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
[TBL] [Abstract][Full Text] [Related]
43. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
Seeber B; Ziehr SC; Gschlieβer A; Moser C; Mattle V; Seger C; Griesmacher A; Concin N; Concin H; Wildt L
Contraception; 2012 Oct; 86(4):345-9. PubMed ID: 22402256
[TBL] [Abstract][Full Text] [Related]
44. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
[TBL] [Abstract][Full Text] [Related]
45. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
46. Non-hormonal and hormonal intrauterine contraception: survey of patients' perceptions in four Latin American countries.
Silva-Filho AL; Lira J; Rocha AL; Ferreira MC; Lamaita RM; Cândido EB; Carneiro MM
Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):213-9. PubMed ID: 26848851
[TBL] [Abstract][Full Text] [Related]
47. Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil.
Bahamondes MV; de Lima Y; Teich V; Bahamondes L; Monteiro I
Contraception; 2012 Sep; 86(3):244-50. PubMed ID: 22459236
[TBL] [Abstract][Full Text] [Related]
48. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
49. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
50. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
51. Levonorgestrel-releasing intrauterine system: why do some women dislike it?
Daud S; Ewies AA
Gynecol Endocrinol; 2008 Dec; 24(12):686-90. PubMed ID: 19172537
[TBL] [Abstract][Full Text] [Related]
52. Two-week postpartum intrauterine contraception insertion: a study of feasibility, patient acceptability and short-term outcomes.
Zerden ML; Stuart GS; Charm S; Bryant A; Garrett J; Morse J
Contraception; 2017 Jan; 95(1):65-70. PubMed ID: 27554014
[TBL] [Abstract][Full Text] [Related]
53. Subject and clinician experience with the levonorgestrel-releasing intrauterine system.
Jensen JT; Nelson AL; Costales AC
Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662
[TBL] [Abstract][Full Text] [Related]
54. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives.
Ferreira JM; Nunes FR; Modesto W; Gonçalves MP; Bahamondes L
Contraception; 2014 Jan; 89(1):17-21. PubMed ID: 24156884
[TBL] [Abstract][Full Text] [Related]
55. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
[TBL] [Abstract][Full Text] [Related]
56. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
[TBL] [Abstract][Full Text] [Related]
57. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
[TBL] [Abstract][Full Text] [Related]
58. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
Nelson AL
Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
[TBL] [Abstract][Full Text] [Related]
59. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
[TBL] [Abstract][Full Text] [Related]
60. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review.
Foran T; Butcher BE; Kovacs G; Bateson D; O'Connor V
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):379-386. PubMed ID: 30382754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
